Not yet recruiting NCT06626581
Iodine Status and Characteristics of Papillary Thyroid Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Iodine excess, Iodine suitable.
- Who it may be relevant to
- Registry conditions: Papillary Thyroid Carcinoma. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Cross-sectional Study on Iodine Status and Characteristics of Papillary Thyroid Cancer
Overview
The effect of iodine on papillary thyroid cancer has been controversial for many years. The investigators designed a cross-sectional study and aimed to explore the relationship between the serum and urine iodine levels and the clinical and molecular characteristics of papillary thyroid cancer.
Interventions
- Dietary supplement Iodine excess
Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) ≥300μg/L - Dietary supplement Iodine suitable
Iodine suitable areas: water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
Primary outcome measures
- Serum and urine iodine levels [Time frame: 1 year from enrollment]
- TNM staging of papillary thyroid cancer [Time frame: 3 month from enrollment]
Eligibility criteria
Inclusion criteria
- Age range: 18\~65 years old, gender not limited;
- Living in the residential area for at least 5 years;
- Patients diagnosed clinically with thyroid cancer and scheduled for thyroid surgery, with pathological diagnosis of papillary thyroid cancer;
- Complete clinical data: including general information, relevant laboratory tests, pathological reports, surgical reports, ultrasound reports, etc.
Exclusion criteria
- Pathological diagnosis of other types of thyroid cancer;
- Diagnosed with other types of cancer;
- There are serious comorbidities of the heart, liver, and kidneys;
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Choi JY, Lee JH, Song Y. Evaluation of Iodine Status among Korean Patients with Papillary Thyroid Cancer Using Dietary and Urinary Iodine. Endocrinol Metab (Seoul). 2021 Jun;36(3):607-618. doi: 10.3803/EnM.2021.1005. Epub 2021 Jun 21. PMID 34154044
- Kim HJ, Park HK, Byun DW, Suh K, Yoo MH, Min YK, Kim SW, Chung JH. Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area. Eur J Nutr. 2018 Mar;57(2):809-815. doi: 10.1007/s00394-016-1370-2. Epub 2017 Mar 3. PMID 28258306
- Zhang X, Zhang F, Li Q, Aihaiti R, Feng C, Chen D, Zhao X, Teng W. The relationship between urinary iodine concentration and papillary thyroid cancer: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022 Oct 31;13:1049423. doi: 10.3389/fendo.2022.1049423. eCollection 2022. PMID 36387866
- Kim K, Cho SW, Park YJ, Lee KE, Lee DW, Park SK. Association between Iodine Intake, Thyroid Function, and Papillary Thyroid Cancer: A Case-Control Study. Endocrinol Metab (Seoul). 2021 Aug;36(4):790-799. doi: 10.3803/EnM.2021.1034. Epub 2021 Aug 11. PMID 34376043
- Lee JH, Hwang Y, Song RY, Yi JW, Yu HW, Kim SJ, Chai YJ, Choi JY, Lee KE, Park SK. Relationship between iodine levels and papillary thyroid carcinoma: A systematic review and meta-analysis. Head Neck. 2017 Aug;39(8):1711-1718. doi: 10.1002/hed.24797. Epub 2017 May 17. PMID 28513893
Identifiers
NCT: NCT06626581 · ShandongPH 20240923